2024
EV016/#559  Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma
Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559  Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.Peer-Reviewed Original Research
1984
Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
Lazo JS, Schwartz PE, MacLusky NJ, Labaree DC, Eisenfeld AJ. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Research 1984, 44: 2265-71. PMID: 6722767.Peer-Reviewed Original ResearchConceptsEstrogen receptorFmol/Tumor samplesMicroM tamoxifenOvarian tumorsOvarian carcinomaColony formationAntiproliferative actionAntiproliferative effectsERc contentHuman epithelial ovarian tumorsSolid ovarian carcinomasERc levelsProgestin receptor levelsEpithelial ovarian tumorsDirect antiproliferative actionCombination of doxorubicinCytosolic estrogen receptorHuman ovarian carcinomaSoft agarMaximum antiproliferative effectsPRC contentsPRc levelsReceptor levelsTamoxifen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply